CTNNB1 (catenin beta 1; HGNC:2514, NCBI Gene 1499) is the gene on chromosome 3p22.1 encoding β-catenin — the dual-function protein that is both the adherens-junction anchor binding E-cadherin to actin and the Wnt pathway's transcriptional effector: when APC's destruction complex fails (or CTNNB1's own phosphorylation sites mutate), β-catenin accumulates, enters the nucleus, and partners TCF to switch on growth genes.
Approved Symbol
CTNNB1 (HGNC:2514)
Chromosomal Locus
3p22.1
Encoded Product
β-catenin — an 85-kDa armadillo-repeat protein (781 aa)
Somatic mutations in HCC, endometrial, and desmoid tumors; Wnt-therapy development's node
Gene Structure & Expression
Genomic organization: 16 exons; exon 3's N-terminal serine-threonine phosphorylation sites (S33, S37, T41, S45) are the hotspot — the residues GSK3β/CK1 phosphorylate to mark the protein for β-TrCP ubiquitination, and their mutation makes a constitutively stable, signaling-on protein.
Expression: Ubiquitous; the protein's fate is post-translational (junction-bound, degraded, or nuclear-signaling) rather than transcriptionally regulated — expression constancy with acute redistribution.
Molecular Function & Pathways
Adherens junctions: β-catenin's armadillo repeats bind E-cadherin's tail, and α-catenin links to actin — epithelial architecture's molecular rivet, see epithelial cells.
Wnt output: Wnt-ligand (or APC-loss) frees β-catenin from destruction; nuclear β-catenin-TCF activates MYC and cyclin D1 (growth), AXIN2 (its own feedback), and LGR5 (stemness) — the pathway's transcriptional arm; exon-3-mutant β-catenin does this without any Wnt, the mutation equivalent of APC loss.
Clinical & Therapeutic Significance
Cancer genetics: CTNNB1 exon-3 mutations in hepatocellular carcinoma (~20–30%), endometrial carcinoma (~25–30%), desmoid tumors (~85%), and hair-follicle tumors (pilomatricoma's classic) — the Wnt cascade's direct oncogenic entry point; mutually exclusive with APC mutation in colorectal cancer (same endpoint).
Therapeutics: Wnt-pathway inhibitors (PORCN, Tankyrase) and β-catenin-cofactor interaction inhibitors in trials — the pathway's stemness dependence as the target; desmoid tumors' β-catenin-driven growth treated with sulindac/antiestrogen strategies and surgery-sparing management.